EUVIMEDEUVIMED entdecken
Crossref

More Evidence, More Options, More Questions

Hiddo J L Heerspink iD, Glenn M Chertow iD

Journal of the American Society of Nephrology · 08.07.2026

DOI: 10.1681/asn.0000001199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 08.07.2026. Verfasst von Hiddo J L Heerspink und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2 inhibitorsrandomized controlled trialsrenin–angiotensin system

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • The George Institute for Global Health, University New South Wales, Sydney, New South Wales, Australia.
  • Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California.

ORCID-Profile: Hiddo J L Heerspink, Glenn M Chertow

Zitieren

APA

Heerspink, H. J. L., & Chertow, G. M. (2026). More Evidence, More Options, More Questions. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001199

Vancouver

Heerspink HJL, Chertow GM. More Evidence, More Options, More Questions. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001199

BibTeX
@article{Heerspink2026,
  author = {Heerspink, Hiddo J L and Chertow, Glenn M},
  title = {More Evidence, More Options, More Questions},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001199}
}
Kostenlos starten →